Trump signs order to fast-track psychedelic research, including ibogaine

President Trump signed an executive order to ease federal restrictions on psychedelic research, including ibogaine, with a $50 million funding commitment and a pathway for ibogaine to be studied and used under the FDA's Right To Try for seriously ill patients. The FDA will also add three psychedelics to the National Priority Voucher program to accelerate reviews, while maintaining oversight and not legalizing the drugs. The move aims to spur new mental-health treatments but underscores safety concerns and the need for more robust clinical trials.